Therapeutic strategies for social anxiety disorder: where are we now?

References

• Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371:1115–1125.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 2013.
   Google Scholar
• Fehm L, Pelissolo A, Furmark T, et al. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2005;15:453–462.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21:169–184.
   PubMed Web of Science ®Google Scholar
• Steinert C, Hofmann M, Leichsenring F, et al. What do we know today about the prospective long-term course of social anxiety disorder? A systematic literature review. J Anxiety Disord. 2013;27:692–702.
   PubMed Web of Science ®Google Scholar
• Lépine JP, Pélissolo A. Why take social anxiety disorder seriously?. Depress Anxiety. 2000;11:87–92.
   PubMed Web of Science ®Google Scholar
• Kessler RC. The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr Scand Suppl. 2003;217:19–27.
   PubMedGoogle Scholar
• Lipsitz JD, Schneier FR. Social phobia Epidemiology and cost of illness. PharmacoEconomics. 2000;18:23–32.
   PubMed Web of Science ®Google Scholar
• Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther. 2016;86:50–67.
   PubMed Web of Science ®Google Scholar
• Rotge J-Y, Grabot D, Aouizerate B, et al. Childhood history of behavioral inhibition and comorbidity status in 256 adults with social phobia. J Affect Disord. 2011;129:338–341.
   PubMed Web of Science ®Google Scholar
• Nagata T, Suzuki F, Teo AR. Generalized social anxiety disorder: A still-neglected anxiety disorder 3 decades since Liebowitz’s review. Psychiatry Clin Neurosci. 2015;69:724–740.
   PubMed Web of Science ®Google Scholar
• Brook CA, Schmidt LA. Social anxiety disorder: A review of environmental risk factors. Neuropsychiatr Dis Treat. 2008;4:123–143.
   PubMedGoogle Scholar
• Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the national comorbidity survey replication. Psychol Med. 2008;38:15–28.
   PubMed Web of Science ®Google Scholar
• Taylor JH, Jakubovski E, Bloch MH. Predictors of anxiety recurrence in the coordinated anxiety learning and Management (CALM) trial. J Psychiatr Res. 2015;65:154–165.
   PubMed Web of Science ®Google Scholar
• Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203–215.
   PubMed Web of Science ®Google Scholar
• Acarturk C, Cuijpers P, van Straten A, et al. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009;39:241–254.
   PubMed Web of Science ®Google Scholar
• Andrews G, Bell C, Boyce P, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry. 2018;52:1109–1172.
   Web of Science ®Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14:S1.
   PubMed Web of Science ®Google Scholar
• Pilling S, Mayo-Wilson E, Mavranezouli I, et al. Recognition, assessment and treatment of social anxiety disorder: summary of NICE guidance. BMJ. 2013;346:f2541.
   PubMedGoogle Scholar
• Hofmann SG. Recent advances in the psychosocial treatment of social anxiety disorder. Depress Anxiety. 2010;27:1073–1076.
   PubMedGoogle Scholar
• Bögels SM. Task concentration training versus applied relaxation, in combination with cognitive therapy, for social phobia patients with fear of blushing, trembling, and sweating. Behav Res Ther. 2006;44:1199–1210.
   PubMed Web of Science ®Google Scholar
• Lobjoie C, Pélissolo A. Efficacy of a cognitive-behavioral group therapy in patients with fear of blushing. L’Encephale. 2012;38:345–350.
   PubMed Web of Science ®Google Scholar
• Stangier U. New developments in cognitive-behavioral therapy for social anxiety disorder. Curr Psychiatry Rep. 2016;18:25.
   PubMed Web of Science ®Google Scholar
• Powers M, Sigmarsson SR, Emmelkamp P. A meta–analytic review of psychological treatments for social anxiety disorder. Int J Cogn Ther. 2008;1:94–113.
   Web of Science ®Google Scholar
• Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011;11:200.
   PubMed Web of Science ®Google Scholar
• Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:368–376.
   PubMed Web of Science ®Google Scholar
• Leichsenring F, Salzer S, Beutel ME, et al. Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder. Am J Psychiatry. 2014;171:1074–1082.
   PubMed Web of Science ®Google Scholar
• Willutzki U, Teismann T, Schulte D. Psychotherapy for social anxiety disorder: long-term effectiveness of resource-oriented cognitive-behavioral therapy and cognitive therapy in social anxiety disorder. J Clin Psychol. 2012;68:581–591.
   PubMed Web of Science ®Google Scholar
• Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies - republished article. Behav Ther. 2016;47:869–885.
   PubMed Web of Science ®Google Scholar
• Hjeltnes A, Molde H, Schanche E, et al. An open trial of mindfulness-based stress reduction for young adults with social anxiety disorder. Scand J Psychol. 2017;58:80–90.
   PubMed Web of Science ®Google Scholar
• Norton AR, Abbott MJ, Norberg MM, et al. A systematic review of mindfulness and acceptance-based treatments for social anxiety disorder. J Clin Psychol. 2015;71:283–301.
   PubMed Web of Science ®Google Scholar
• Craske MG, Niles AN, Burklund LJ, et al. Randomized controlled trial of cognitive behavioral therapy and acceptance and commitment therapy for social phobia: outcomes and moderators. J Consult Clin Psychol. 2014;82:1034–1048.
   PubMed Web of Science ®Google Scholar
• Koszycki D, Benger M, Shlik J, et al. Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007;45:2518–2526.
   PubMed Web of Science ®Google Scholar
• Goldin PR, Morrison AS, Jazaieri H, et al. Trajectories of social anxiety, cognitive reappraisal, and mindfulness during an RCT of CBGT versus MBSR for social anxiety disorder. Behav Res Ther. 2017;97:1–13.
   PubMed Web of Science ®Google Scholar
• Hedman E, Andersson G, Ljótsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PloS One. 2011;6:e18001.
   PubMed Web of Science ®Google Scholar
• Goetter EM, Frumkin MR, Palitz SA, et al. Barriers to mental health treatment among individuals with social anxiety disorder and generalized anxiety disorder. Psychol Serv. 2018.
   Google Scholar
• Andrews G, Newby JM, Williams AD. Internet-delivered cognitive behavior therapy for anxiety disorders is here to stay. Curr Psychiatry Rep. 2014;17:533.
   Web of Science ®Google Scholar
• El Alaoui S, Hedman-Lagerlöf E, Ljótsson B, et al. Does internet-based cognitive behaviour therapy reduce healthcare costs and resource use in treatment of social anxiety disorder? A cost-minimisation analysis conducted alongside a randomised controlled trial. BMJ Open. 2017;7:e017053.
   PubMedGoogle Scholar
• Hedman E, El Alaoui S, Lindefors N, et al. Clinical effectiveness and cost-effectiveness of Internet- vs. group-based cognitive behavior therapy for social anxiety disorder: 4-year follow-up of a randomized trial. Behav Res Ther. 2014;59:20–29.
   PubMed Web of Science ®Google Scholar
• Kampmann IL, Emmelkamp PMG, Morina N. Meta-analysis of technology-assisted interventions for social anxiety disorder. J Anxiety Disord. 2016;42:71–84.
   PubMed Web of Science ®Google Scholar
• Johansson R, Hesslow T, Ljótsson B, et al. Internet-based affect-focused psychodynamic therapy for social anxiety disorder: A randomized controlled trial with 2-year follow-up. Psychotherapy. 2017;54:351–360.
   PubMed Web of Science ®Google Scholar
• Ivanova E, Lindner P, Ly KH, et al. Guided and unguided acceptance and commitment therapy for social anxiety disorder and/or panic disorder provided via the internet and a smartphone application: A randomized controlled trial. J Anxiety Disord. 2016;44:27–35.
   PubMed Web of Science ®Google Scholar
• Bouchard S, Dumoulin S, Robillard G, et al. Virtual reality compared with in vivo exposure in the treatment of social anxiety disorder: a three-arm randomised controlled trial. Br J Psychiatry J Ment Sci. 2017;210:276–283.
   PubMed Web of Science ®Google Scholar
• Safir MP, Wallach HS, Bar-Zvi M. Virtual reality cognitive-behavior therapy for public speaking anxiety: one-year follow-up. Behav Modif. 2012;36:235–246.
   PubMed Web of Science ®Google Scholar
• Anderson PL, Price M, Edwards SM, et al. Virtual reality exposure therapy for social anxiety disorder: a randomized controlled trial. J Consult Clin Psychol. 2013;81:751–760.
   PubMed Web of Science ®Google Scholar
• Kampmann IL, Emmelkamp PMG, Hartanto D, et al. Exposure to virtual social interactions in the treatment of social anxiety disorder: A randomized controlled trial. Behav Res Ther. 2016;77:147–156.
   PubMed Web of Science ®Google Scholar
• Morina N, Brinkman W-P, Hartanto D, et al. Social interactions in virtual reality exposure therapy: A proof-of-concept pilot study. Technol Health Care Off J Eur Soc Eng Med. 2015;23:581–589.
   PubMed Web of Science ®Google Scholar
• Lin XB, Lee T-S, Cheung YB, et al. Exposure therapy with personalized real-time arousal detection and feedback to alleviate social anxiety symptoms in an analogue adult sample: pilot proof-of-concept randomized controlled Trial. JMIR Ment Health. 2019;6:e13869.
   PubMed Web of Science ®Google Scholar
• Heeren A, Mogoașe C, Philippot P, et al. Attention bias modification for social anxiety: A systematic review and meta-analysis. Clin Psychol Rev. 2015;40:76–90.
   PubMed Web of Science ®Google Scholar
• Beard C. Cognitive bias modification for anxiety: current evidence and future directions. Expert Rev Neurother. 2011;11:299–311.
   PubMed Web of Science ®Google Scholar
• Kuckertz JM, Amir N. Attention bias modification for anxiety and phobias: current status and future directions. Curr Psychiatry Rep. 2015;17:9.
   PubMed Web of Science ®Google Scholar
• Ollendick TH, White SW, Richey J, et al. Attention bias modification treatment for adolescents with social anxiety disorder. Behav Ther. 2019;50:126–139.
   PubMed Web of Science ®Google Scholar
• Amir N, Weber G, Beard C, et al. The effect of a single-session attention modification program on response to a public-speaking challenge in socially anxious individuals. J Abnorm Psychol. 2008;117:860–868.
   PubMed Web of Science ®Google Scholar
• Amir N, Beard C, Taylor CT, et al. Attention training in individuals with generalized social phobia: A randomized controlled trial. J Consult Clin Psychol. 2009;77:961–973.
   PubMed Web of Science ®Google Scholar
• Schmidt NB, Richey JA, Buckner JD, et al. Attention training for generalized social anxiety disorder. J Abnorm Psychol. 2009;118:5–14.
   PubMed Web of Science ®Google Scholar
• Heeren A, Reese HE, McNally RJ, et al. Attention training toward and away from threat in social phobia: effects on subjective, behavioral, and physiological measures of anxiety. Behav Res Ther. 2012;50:30–39.
   PubMed Web of Science ®Google Scholar
• Naim R, Kivity Y, Bar-Haim Y, et al. Attention and interpretation bias modification treatment for social anxiety disorder: A randomized clinical trial of efficacy and synergy. J Behav Ther Exp Psychiatry. 2018;59:19–30.
   PubMed Web of Science ®Google Scholar
• Boettcher J, Leek L, Matson L, et al. Internet-based attention bias modification for social anxiety: a randomised controlled comparison of training towards negative and training towards positive cues. PloS One. 2013;8:e71760.
   PubMed Web of Science ®Google Scholar
• Julian K, Beard C, Schmidt NB, et al. Attention training to reduce attention bias and social stressor reactivity: an attempt to replicate and extend previous findings. Behav Res Ther. 2012;50:350–358.
   PubMed Web of Science ®Google Scholar
• Rapee RM, MacLeod C, Carpenter L, et al. Integrating cognitive bias modification into a standard cognitive behavioural treatment package for social phobia: a randomized controlled trial. Behav Res Ther. 2013;51:207–215.
   PubMed Web of Science ®Google Scholar
• Carlbring P, Apelstrand M, Sehlin H, et al. Internet-delivered attention bias modification training in individuals with social anxiety disorder–a double blind randomized controlled trial. BMC Psychiatry. 2012;12:66.
   PubMed Web of Science ®Google Scholar
• Price RB, Kuckertz JM, Amir N, et al. Less is more: patient-level meta-analysis reveals paradoxical dose-response effects of a computer-based social anxiety intervention targeting attentional bias. Depress Anxiety. 2017;34:1106–1115.
   PubMed Web of Science ®Google Scholar
• Emmelkamp PMG. Attention bias modification: the Emperor’s new suit? BMC Med. 2012;10:63.
   PubMed Web of Science ®Google Scholar
• Heeren A, Lievens L, Philippot P. How does attention training work in social phobia: disengagement from threat or re-engagement to non-threat? JAnxiety Disord. 2011;25:1108–1115.
   PubMed Web of Science ®Google Scholar
• Liang C-W, Hsu W-Y. Effects of attention bias modification with short and long stimulus-duration: A randomized experiment with individuals with subclinical social anxiety. Psychiatry Res. 2016;240:80–87.
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544–549.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16:77–84.
   PubMed Web of Science ®Google Scholar
• Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017;10:CD001206.
   PubMedGoogle Scholar
• Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008;8:235–257.
   PubMedGoogle Scholar
• Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:118–125.
   PubMed Web of Science ®Google Scholar
• Blomhoff S, Haug TT, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry J Ment Sci. 2001;179:23–30.
   PubMed Web of Science ®Google Scholar
• Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71:1058–1067.
   PubMed Web of Science ®Google Scholar
• Nordahl HM, Vogel PA, Morken G, et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychother Psychosom. 2016;85:346–356.
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005;177:280–288.
   PubMed Web of Science ®Google Scholar
• Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708–713.
   PubMed Web of Science ®Google Scholar
• Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100:193–198.
   PubMed Web of Science ®Google Scholar
• Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group. Br J Psychiatry J Ment Sci. 1999;175:120–126.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Stein MB, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63:66–74.
   PubMed Web of Science ®Google Scholar
• Book SW, Thomas SE, Randall PK, et al. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord. 2008;22:310–318.
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kielbasa W, Iyengar S, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010;20:80–87.
   PubMed Web of Science ®Google Scholar
• Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756–760.
   PubMed Web of Science ®Google Scholar
• Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007;10:263–274.
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368–1371.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:785–792.
   PubMed Web of Science ®Google Scholar
• Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22:257–262.
   PubMed Web of Science ®Google Scholar
• Furmark T, Appel L, Michelgård A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005;58:132–142.
   PubMed Web of Science ®Google Scholar
• Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:488–496.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–198.
   PubMed Web of Science ®Google Scholar
• Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26:213–220.
   PubMed Web of Science ®Google Scholar
• Blanco C, Bragdon LB, Schneier FR, et al. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013;16:235–249.
   PubMed Web of Science ®Google Scholar
• Halaby A, Haddad R, Naja W. Non-Antidepressant treatment of social anxiety disorder: A review. Curr Clin Pharmacol. 2015;10:126–130.
   PubMed Web of Science ®Google Scholar
• Silberman EK. The role of benzodiazepines in treating social anxiety disorder. Am J Psychiatry. 2014;171:795.
   PubMed Web of Science ®Google Scholar
• Pignon B, Schürhoff F, Baudin G, et al. Relationship between incidence and prevalence in psychotic disorders: an incidence-prevalence-mortality model. Int J Methods Psychiatr Res. 2018;27:e1719.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9:248–312.
   PubMed Web of Science ®Google Scholar
• Crippa JAS, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol Oxf Engl. 2011;25:121–130.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2011;36:1219–1226.
   PubMed Web of Science ®Google Scholar
• Mandolini GM, Lazzaretti M, Pigoni A, et al. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018;27:327–335.
   PubMed Web of Science ®Google Scholar
• Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry. 2016;79:213–221.
   PubMed Web of Science ®Google Scholar
• Labuschagne I, Phan KL, Wood A, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol. 2012;15:883–896.
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34:917–923.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Hanover R, Draine A, et al. Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depress Anxiety. 2016;33:1081–1089.
   PubMed Web of Science ®Google Scholar
• Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacol. 2018;43:325–333.
   PubMed Web of Science ®Google Scholar
• Glue P, Neehoff SM, Medlicott NJ, et al. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32:663–667.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30:183–192.
   PubMed Web of Science ®Google Scholar
• Gingnell M, Frick A, Engman J, et al. Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial. Br J Psychiatry J Ment Sci. 2016;209:229–235.
   PubMed Web of Science ®Google Scholar
• Chartier MJ, Walker JR, Stein MB. Considering comorbidity in social phobia. Soc Psychiatry Psychiatr Epidemiol. 2003;38:728–734.
   PubMed Web of Science ®Google Scholar
• Acarturk C, de Graaf R, van Straten A, et al. Social phobia and number of social fears, and their association with comorbidity, health-related quality of life and help seeking: a population-based study. Soc Psychiatry Psychiatr Epidemiol. 2008;43:273–279.
   PubMed Web of Science ®Google Scholar
• Koyuncu A, İnce E, Ertekin E, et al. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs Context. 2019;8:212573.
   PubMedGoogle Scholar
• Mennin DS, Heimberg RG, Jack MS. Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. J Anxiety Disord. 2000;14:325–343.
   PubMed Web of Science ®Google Scholar
• Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am. 2010;33:557–577.
   PubMed Web of Science ®Google Scholar
• Koyuncu A, Alkın T, Tükel R. Development of social anxiety disorder secondary to attention deficit/hyperactivity disorder (the developmental hypothesis). Early Interv Psychiatry. 2018;12:269–272.
   PubMed Web of Science ®Google Scholar
• Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26:212–221.
   PubMed Web of Science ®Google Scholar
• Koyuncu A, Çelebi F, Ertekin E, et al. Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series. Ther Adv Psychopharmacol. 2017;7:241–247.
   PubMed Web of Science ®Google Scholar
• Beidel DC, Ferrell C, Alfano CA, et al. The treatment of childhood social anxiety disorder. Psychiatr Clin North Am. 2001;24:831–846.
   PubMed Web of Science ®Google Scholar
• Ryan JL, Warner CM. Treating adolescents with social anxiety disorder in schools. Child Adolesc Psychiatr Clin N Am. 2012;21: 105–118, ix.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, He J, Burstein M, et al. Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2011;50:32–45.
   PubMed Web of Science ®Google Scholar
• Segool NK, Carlson JS. Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety. 2008;25:620–631.
   PubMed Web of Science ®Google Scholar
• Melfsen S, Kühnemund M, Schwieger J, et al. Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study. Child Adolesc Psychiatr Ment Health. 2011;5:5.
   PubMedGoogle Scholar
• Masia-Warner C, Klein RG, Dent HC, et al. School-based intervention for adolescents with social anxiety disorder: results of a controlled study. J Abnorm Child Psychol. 2005;33:707–722.
   PubMed Web of Science ®Google Scholar
• Garcia-Lopez L-J, Olivares J, Beidel D, et al. Efficacy of three treatment protocols for adolescents with social anxiety disorder: a 5-year follow-up assessment. J Anxiety Disord. 2006;20:175–191.
   PubMed Web of Science ®Google Scholar
• Beidel DC, Turner SM, Sallee FR, et al. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46:1622–1632.
   PubMed Web of Science ®Google Scholar
• March JS, Entusah AR, Rynn M, et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62:1149–1154.
   PubMed Web of Science ®Google Scholar
• Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359:2753–2766.
   PubMed Web of Science ®Google Scholar
• Dalrymple K, D’Avanzato C. Differentiating the subtypes of social anxiety disorder. Expert Rev Neurother. 2013;13:1271–1283.
   PubMed Web of Science ®Google Scholar
• Moukheiber A, Rautureau G, Perez-Diaz F, et al. Gaze avoidance in social phobia: objective measure and correlates. Behav Res Ther. 2010;48:147–151.
   PubMed Web of Science ®Google Scholar
• Jazaieri H, Morrison AS, Goldin PR, et al. The role of emotion and emotion regulation in social anxiety disorder. Curr Psychiatry Rep. 2015;17:531.
   PubMed Web of Science ®Google Scholar